Roche lymphoma drug drives high remission rate, longer survival: study Ruby Khatun Khatun12 Dec 2017 10:00 AM ISTAn experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced,...